News provided by
Share this article
Share this article
VANCOUVER, BC, Dec. 2, 2021 /CNW/ - Yumy Bear Goods Inc., (CSE: YUMY) ("Yumy Bear" or the "Company") has begun selling its low sugar "Better for You" candy at Pure Integrative Pharmacy Chain. Pure Integrative Pharmacy is an actively growing pharmaceutical chain that was founded in 1999 and has 17 retail locations. Pure Integrative Pharmacy is a full-service pharmacy with a focus on evidence-based modalities of medicine in a way that optimizes the health and wellness brands in British Columbia. Pure Pharmacy is also a subsidiary of one of Canada's largest conglomerates which operates more than 250 locations of various industries, having over 45,000 employees and annual sales north of $10 billion. The total size of the umbrella company has over 45,000 employees and annual sales north of $10 billion. The launch into Pure Integrative Pharmacy continues Yumy Bear's focus on pharmacies and further pushing its product into some of the world's largest conglomerates. The Company will continue to expand its footprint in the pharmaceutical industry as it provides a great way for their patients to optimize their health and diets. "This furthers our retail presence of our products into pharmacies and furthers the sentiment that Yumy Bear is the perfect grab-and-go product that retailers and consumers alike are looking for. Pure pharmacies believe healthier, and natural products are crucial to a great overall well-being in their patients. Our products are a perfect substitute to existing brands to optimize patients' health," states Chief Executive Officer, Erica Williams. Yumy Bear is an affordable health-conscious low-sugar plant-based confectionery company based in Vancouver, British Columbia and it has developed a portfolio of healthier gelatine-free candies made from non-GMO ingredients with proprietary recipes. All of its products are free of gelatin, soy, gluten, nuts, dairy, eggs, sugar alcohols, artificial sweeteners and genetically modified organisms. Cautionary Statement Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable securities legislation. The information in this news release about future plans and objectives of the Company, are forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Company at the time it was made, and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: general business, economic and social uncertainties; local and global market and economic uncertainties arising in respect of the COVID-19 pandemic; litigation, availability of key product ingredients, legislative, environmental and other judicial, regulatory, political and competitive developments; the ability to effectively expand manufacturing and production capacity; the ability to obtain retail partners to distribute Company products, the success of market initiatives and the ability to grow brand awareness; the ability to attract, maintain and expand relationships with key strategic vendors; our ability to predict consumer taste preferences; delay or failure to receive regulatory approvals; the sufficiency of our cash to meet liquidity needs; those additional risks set out in the Company's public documents filed on SEDAR at www.sedar.com ; and other matters discussed in this news release. Accordingly, the forward-looking statements discussed in this release may not occur and could differ materially as a result of these known and unknown risk factors and uncertainties affecting the Company. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward- looking statement, whether as a result of new information, future events, or otherwise. SOURCE Yumy Bear Goods Inc.
For further information: YUMY BEAR GOODS INC., Erica Williams, CEO, Telephone: (604) 449-2026, Email: [email protected]
×

16:18 ET
Yumy Bear Goods Further Expands its Retail Presence and Receives Order from Premier Pharmacy Pure Integrative Pharmacy

News provided by
Share this article
Share this article
VANCOUVER, BC, Nov. 24, 2021 /CNW/ - Yumy Bear Goods Inc., (CSE: YUMY) ("Yumy Bear Candy" or the "Company") has began selling its low sugar "Better for You" candy at London Drugs. London Drugs was founded in 1945 and has over 78 retail locations. London Drugs is one of the most established longest standing pharmacy brands in British Columbia. London Drugs is a subsidiary of the Georgia Main Food Group. The Georgia Main Food group established in 1903 is the parent company for the large food brands IGA and Fresh St. Market. The company operates hundreds of locations and thousands of employees. "This marks our initial launch of focusing on pharmacies and supplement retailers. Yumy Bear is the perfect grab and go product that retailers and consumers alike are looking for. By getting our foot in the door with London Drugs one of the most established brands, we hope to increase our footprint with other pharmacies, and the Georgia Main Group," states CEO Erica Williams. Yumy Bear is an affordable health-conscious low-sugar plant-based confectionery company based in Vancouver, British Columbia and it has developed a portfolio of healthier gelatine-free candies made from non-GMO ingredients with proprietary recipes. All of its products are free of gelatin, soy, gluten, nuts, dairy, eggs, sugar alcohols, artificial sweeteners and genetically modified organisms. Cautionary Statement Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable securities legislation. The information in this news release about future plans and objectives of the Company, are forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Company at the time it was made, and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: general business, economic and social uncertainties; local and global market and economic uncertainties arising in respect of the COVID-19 pandemic; litigation, availability of key product ingredients, legislative, environmental and other judicial, regulatory, political and competitive developments; the ability to effectively expand manufacturing and production capacity; the ability to obtain retail partners to distribute Company products, the success of market initiatives and the ability to grow brand awareness; the ability to attract, maintain and expand relationships with key strategic vendors; our ability to predict consumer taste preferences; delay or failure to receive regulatory approvals; the sufficiency of our cash to meet liquidity needs; those additional risks set out in the Company's public documents filed on SEDAR at www.sedar.com ; and other matters discussed in this news release. Accordingly, the forward-looking statements discussed in this release may not occur and could differ materially as a result of these known and unknown risk factors and uncertainties affecting the Company. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward- looking statement, whether as a result of new information, future events, or otherwise. SOURCE Yumy Bear Goods Inc.
For further information: YUMY BEAR GOODS INC., Erica Williams, CEO, Telephone: (604) 449-2026, Email: [email protected]
×

16:05 ET
Yumy Bear Goods Receives Order from Premier Pharmacy London Drugs

Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture And Distribution Of Drugs Due To Insanitary Conditions
SILVER SPRING, Md., Sept.
Sep 17, 2021 11:46 AM EDT
SILVER SPRING, Md., Sept. 17, 2021 /PRNewswire/ -- The U.S. District Court for the Middle District of Florida has entered a consent decree of permanent injunction that prohibits a Florida-based company from producing or distributing any drugs until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other requirements. According to the complaint, filed by the U.S. Department of Justice on behalf of the U.S. Food and Drug Administration (FDA), Premier Pharmacy Labs Inc. and the company's owner, Vern A. Allen, manufactured and distributed drugs made under insanitary conditions at Premier Pharmacy's facility, despite multiple warnings from the FDA. Premier stopped manufacturing drugs following an FDA inspection in June 2019. "Premier Pharmacy and its owner placed patients at significant risk. Outsourcing facilities must follow good manufacturing practice to ensure patients are not exposed to poor quality, potentially harmful drugs," said Donald D. Ashley, J.D., director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research. "We will continue to take appropriate enforcement actions to ensure that companies follow important safety requirements to avoid putting patients' health at risk." The consent decree requires Premier Pharmacy to not engage in any compounding operations or distribution until it completes corrective actions, to ensure the company and its facility are in compliance with the FD&C Act. Under the consent decree, Premier Pharmacy may not resume compounding operations until it establishes and implements, among other things, a comprehensive quality control system and receives authorization from the FDA. The complaint alleged that Premier Pharmacy manufactured and distributed drugs, including drugs that were intended to be sterile, that were adulterated because the drugs were made under insanitary conditions and in violation of good manufacturing practice requirements under the FD&C Act. Insanitary conditions can cause a compounded drug to become contaminated or otherwise cause patient harm. According to the complaint, Premier Pharmacy also manufactured and distributed drugs that were neither approved nor exempt from approval because the products did not meet all statutory requirements for outsourcing facilities. In the spring of 2014, the FDA conducted an inspection of Premier Pharmacy that resulted in a warning letter  for insanitary conditions and other violations of the FD&C Act. The FDA conducted a follow-up inspection in June 2016, leading to a regulatory meeting with the company in January 2018. In April 2018, Premier Pharmacy recalled  affected sterile injectable products due to potential lack of sterility assurance. The FDA conducted another follow-up inspection which started in April 2019. In June 2019, following the April inspection and the FDA's recommendation to recall, Premier Pharmacy recalled all unexpired drugs intended to be sterile. Premier Pharmacy had been registered as an outsourcing facility for compounded drugs; however, the company deregistered in 2019 and has since stopped compounding drugs. Compounded drugs can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug product. Compounded drugs are not approved by the FDA and, therefore, have not been evaluated for safety or efficacy. Related Information:

Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture And Distribution Of Drugs Due To Insanitary Conditions

News provided by
Share this article
Share this article
SILVER SPRING, Md., Sept. 17, 2021 /PRNewswire/ -- The U.S. District Court for the Middle District of Florida has entered a consent decree of permanent injunction that prohibits a Florida-based company from producing or distributing any drugs until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other requirements. According to the complaint, filed by the U.S. Department of Justice on behalf of the U.S. Food and Drug Administration (FDA), Premier Pharmacy Labs Inc. and the company's owner, Vern A. Allen, manufactured and distributed drugs made under insanitary conditions at Premier Pharmacy's facility, despite multiple warnings from the FDA. Premier stopped manufacturing drugs following an FDA inspection in June 2019. "Premier Pharmacy and its owner placed patients at significant risk. Outsourcing facilities must follow good manufacturing practice to ensure patients are not exposed to poor quality, potentially harmful drugs," said Donald D. Ashley, J.D., director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research. "We will continue to take appropriate enforcement actions to ensure that companies follow important safety requirements to avoid putting patients' health at risk." The consent decree requires Premier Pharmacy to not engage in any compounding operations or distribution until it completes corrective actions, to ensure the company and its facility are in compliance with the FD&C Act. Under the consent decree, Premier Pharmacy may not resume compounding operations until it establishes and implements, among other things, a comprehensive quality control system and receives authorization from the FDA. The complaint alleged that Premier Pharmacy manufactured and distributed drugs, including drugs that were intended to be sterile, that were adulterated because the drugs were made under insanitary conditions and in violation of good manufacturing practice requirements under the FD&C Act. Insanitary conditions can cause a compounded drug to become contaminated or otherwise cause patient harm. According to the complaint, Premier Pharmacy also manufactured and distributed drugs that were neither approved nor exempt from approval because the products did not meet all statutory requirements for outsourcing facilities. In the spring of 2014, the FDA conducted an inspection of Premier Pharmacy that resulted in a warning letter  for insanitary conditions and other violations of the FD&C Act. The FDA conducted a follow-up inspection in June 2016, leading to a regulatory meeting with the company in January 2018. In April 2018, Premier Pharmacy recalled  affected sterile injectable products due to potential lack of sterility assurance. The FDA conducted another follow-up inspection which started in April 2019. In June 2019, following the April inspection and the FDA's recommendation to recall, Premier Pharmacy recalled all unexpired drugs intended to be sterile. Premier Pharmacy had been registered as an outsourcing facility for compounded drugs; however, the company deregistered in 2019 and has since stopped compounding drugs. Compounded drugs can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug product. Compounded drugs are not approved by the FDA and, therefore, have not been evaluated for safety or efficacy. Related Information:

11:46 ET
Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture and Distribution of Drugs Due t...

0
The company has announced a recall of products which were intended to be sterile after a lack of sterility assurance. Premier Pharmacy Labs has released an announcement to recall all unexpired products which were intended to be sterile due to a lack of sterility assurance. The US Food and Drug Administration ’s (FDA) inspection of the company’s facility in Florida found insufficient environmental controls, potential cross contamination and a lack of process validation. The results from the inspection prompted the company to voluntarily recall the products. The inspection took place from 20 April to 12 June. A nationwide US recall is being completed at consumer level. Premier Pharmacy has so far received no reports of adverse effects in patients. The company, which works with hospitals, surgery centres and physician clinics, said patients in possession of the affected medications should quarantine the product, discontinue use and destroy the pharmaceuticals. Premier Pharmacy stated that the recall was being conducted due to an “abundance of caution.”
This is the second voluntary recall Premier Pharmacy Labs has issued as a result of potential lack of sterility assurance since last spring.

Premier Pharmacy Labs recalls products after FDA inspection

TCGRx is a supplier of pharmacy automation, offering scalable solutions that range from simple packaging technology to enterprise-wide perpetual inventory management. TCGRX solutions are specifically designed to make pharmacies and their processes more efficient. The company provides comprehensive workflow automation, including design and consultation services, to offer in-patient, outpatient, and long-term care pharmacies a fully featured, integrated solution.

TCGRx

Premier Pharmacy Services has partnered with TCGRx to develop an innovative , customizable workflow solution to increase services to its patients .

Premier Pharmacy Services Installs the Complete ShortCycleRx® Workflow Solution From TCGRx

Pharma Supply Chain

Provides services to the community of Rainer Valley and to long term care customers in the Greater Puget Sound area. Services include perscriptions, medical supplies, I.V. therapy and oxygen supplies and service.

Name	Work History	Title	Status
Dirk Allison		Chief Executive Officer	Current
Don Hughes		Chief Financial Officer	Current

Name	Dirk Allison	Don Hughes
Work History
Title	Chief Executive Officer	Chief Financial Officer
Status	Current	Current

Wells Fargo Success Story

3M Success Story

Platform Overview

Premier Pharmacy

Executives

Premier Pharmacy Management Team

2 Team Members

Discover the right solution for your team